Buy Zuranolone (Zurzuvae) Cas 1632051-40-1

Zuranolone, sold under the brand name Zurzuvae, is a medication used for the treatment of postpartum depression.^[2] It is taken by mouth.^[2] Zuranolone is a neuroactive steroid which enhances the activity of the neurotransmitter gamma-aminobutyric acid (GABA) and is thought to exert antidepressant effects by enhancing GABAergic inhibition.^[4][9][10]

The most common side effects include drowsiness, dizziness, diarrhea, fatigue, nasopharyngitis, and urinary tract infection.^[2][11]

Zuranolone was approved for medical use in the United States for the treatment of postpartum depression in August 2023.^[11] It was developed by Sage Therapeutics and Biogen.^[12]

Zuranolone is indicated for the treatment of postpartum depression.^[2][11]

The most common side effects include drowsiness, dizziness, diarrhea, fatigue, and urinary tract infection.^[11]

The US prescribing information contains a boxed warning noting that zuranolone can impact a person’s ability to drive and perform other potentially hazardous activities.^[11] The use of zuranolone may cause suicidal thoughts and behavior.^[11] Zuranolone may also cause fetal harm.^[11]

Zuranolone was developed as an improvement on the intravenously administered neurosteroid brexanolone, with high oral bioavailability and a biological half-life suitable for once-daily administration.^[9][13] Its half-life is around 16 to 23 hours, compared to approximately 9 hours for brexanolone.^[7][8]

The efficacy of zuranolone for the treatment of postpartum depression in adults was demonstrated in two randomized, double-blind, placebo-controlled, multicenter studies.^[11] The trial participants were women with postpartum depression who met the Diagnostic and Statistical Manual of Mental Disorders criteria for a major depressive episode and whose symptoms began in the third trimester or within four weeks of delivery.^[11] In study 1, participants received 50 mg of zuranolone or placebo once daily in the evening for 14 days.^[11] In study 2, participants received another zuranolone product that was approximately equal to 40 mg of zuranolone or placebo, also for 14 days.^[11] Participants in both studies were monitored for at least four weeks after the 14-day treatment.^[11] The primary endpoint of both studies was the change in depressive symptoms using the total score from the 17-item Hamilton depression rating scale (HAMD-17), measured at day 15.^[11] Participants in the zuranolone groups showed significantly more improvement in their symptoms compared to those in the placebo groups.^[11] The treatment effect was maintained at day 42—four weeks after the last dose of zuranolone.^[11]